NeuroMab™ Anti-Tau BBB Shuttle Antibody(NRZP-1022-ZP3091)

Figure 1 shows antibody binding to phosphorylated Tau in AD and tau disease patient brain slices using the ACI-36-3A8-Ab1 antibody using TAUPIR.

Figure 2 shows the effect of anti-Tau antibody treatment after a 1-week in vivo study of the pTau epitope pT231 using MSD.

Figure 3 shows the effect of anti-Tau antibody treatment after a 1-week in vivo study of the pTau epitope pT231 using MSD.

Figure 4 shows the pTau epitope western blot after anti-Tau antibody treatment in a 1-month in vivo study.

Figure 5 shows pTau epitope western blot results after anti-Tau antibody treatment in a 3-month in vivo study.

Figure 6 shows the pTau epitope western blot after anti-Tau antibody treatment for a 3-month in vivo study using biGT biomouse.

Figure 7 shows pTau epitope Western blot results after anti-Tau antibody treatment for a 3-month in vivo study using biGT biomouse.

Figure 8 shows pTau epitope western blot results after anti-Tau antibody treatment for a 3-month in vivo study using biGT biomouse.

Figure 9 shows IHC after anti-Tau antibody treatment by ACI-36-2B6-Ab1 in a 3-month in vivo study.

Figure 10 shows IHC following anti-Tau antibody treatment with ACI-36-2B6-Ab1 in a 3-month in vivo study.

Figure 11 shows the Morris water maze results after ACI-36-2B6-Ab1 anti-Tau antibody treatment in a 3-month in vivo study.

Figure 12 shows the Morris water maze results after ACI-36-3A8-AM anti-Tau antibody treatment in a 3-month in vivo study.